CD8A and cancer: A recent study found that cancer-IgG can be secreted into the tumor microenvironment and can bind to sialic acid–binding immunoglobulin-type lectins of CD4+ and CD8+ effector T cells to directly inhibit the proliferation of CD4+ and CD8+ T cells and significantly promote tumor growth (16).